ImClone Systems (NASDAQ: IMCL) submitted an application to the FDA to broaden the use of ERBITUX to include first-line treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE